DXCM DEXCOM INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1093557 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.0%
TTM net income YoY37.5%
TTM EPS YoY41.1%
Revenue 3-yr CAGR14.5%
Net income 3-yr CAGR38.0%
Margins
Gross margin63.4%
Operating margin24.0%
Net margin19.4%
FCF margin21.5%
EBITDA margin29.4%
Returns
ROE37.7%
ROA14.4%
ROIC (approx.)78.0%
Asset turnover0.74x
Leverage & solvency
Liabilities / assets59.4%
Debt / equity0.00x
Current ratio1.74x
Interest coverage91.33x
Cash quality & payout
Operating cash flow / net income1.43x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue6.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.66B | $4.03B | $3.62B | $2.91B | $2.45B |
| Cost of revenue | $1.86B | $1.59B | $1.33B | $1.03B | $768.00M |
| Gross profit | $2.80B | $2.44B | $2.29B | $1.88B | $1.68B |
| R&D expense | $599.10M | $552.40M | $505.80M | $484.20M | $517.10M |
| SG&A expense | $1.29B | $1.29B | $1.19B | $1.01B | $810.50M |
| Operating income | $911.80M | $600.00M | $597.70M | $391.20M | $265.80M |
| Interest expense | $18.30M | $19.00M | $20.30M | $18.60M | $18.80M |
| Pretax income | $1.09B | $709.00M | $710.40M | $390.80M | $256.80M |
| Income tax | $252.10M | $132.80M | $168.90M | $49.60M | $39.90M |
| Net income | $836.30M | $576.20M | $541.50M | $341.20M | $216.90M |
| EBITDA | $1.16B | $817.70M | $783.70M | $547.10M | $367.80M |
| EPS (basic) | 2.14 | 1.46 | 1.40 | 0.88 | 0.56 |
| EPS (diluted) | 2.09 | 1.42 | 1.30 | 0.82 | 0.53 |
| Weighted avg. shares (diluted) | 405.50M | 412.70M | 425.50M | 427.50M | 428.80M |
| Balance sheet | |||||
| Cash & equivalents | $917.70M | $607.30M | $566.30M | $643.30M | $1.05B |
| Short-term investments | — | $1.73B | $2.16B | $1.81B | $1.36B |
| Receivables | $1.22B | $1.01B | $973.90M | $713.30M | $514.30M |
| Inventory | $629.10M | $542.60M | $559.60M | $306.70M | $357.30M |
| Current assets | $4.03B | $4.30B | $4.43B | $3.67B | $3.68B |
| PP&E, net | $1.56B | $1.34B | $1.11B | $1.06B | $801.80M |
| Goodwill | $24.20M | $22.80M | $25.20M | $25.70M | $26.50M |
| Intangibles | $70.80M | $103.40M | $134.50M | $173.30M | $31.50M |
| Total assets | $6.34B | $6.48B | $6.26B | $5.39B | $4.93B |
| Current liabilities | $2.14B | $2.93B | $1.56B | $1.84B | $720.80M |
| Total liabilities | $3.59B | $4.38B | $4.20B | $3.26B | $2.89B |
| Shareholders' equity | $2.75B | $2.10B | $2.07B | $2.13B | $2.04B |
| Shares outstanding | 384.80M | 390.70M | 385.40M | 386.30M | 388.00M |
| Cash flow statement | |||||
| Operating cash flow | $1.44B | $989.50M | $748.50M | $669.50M | $442.50M |
| Capital expenditure | $363.50M | $358.80M | $236.60M | $364.80M | $389.20M |
| Free cash flow | $1.08B | $630.70M | $511.90M | $304.70M | $53.30M |
| Investing cash flow | $536.00M | -$207.50M | -$507.20M | -$521.50M | -$216.10M |
| Financing cash flow | -$1.69B | -$734.80M | -$318.60M | -$552.50M | $10.40M |
| Depreciation & amortization | $251.80M | $217.70M | $186.00M | $155.90M | $102.00M |
| Stock-based compensation | $159.60M | $170.40M | $150.80M | $126.50M | $113.40M |
| Share buybacks | $500.00M | $750.00M | $688.70M | $557.70M | $0 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.